Effect of diet-induced obesity on protein expression in insulin signalling pathways of skeletal muscle in male Wistar rats by Fatani, Sameer et al.
Effect of diet-induced obesity on protein expression in insulin signalling pathways of
skeletal muscle in male Wistar rats
Fatani, Sameer; Abubakari, Abdul-Razak; Itua, Imose; Wong, Christopher; Thomas, Cecil;
Naderali, Ebrahim K.
Published in:






Publisher's PDF, also known as Version of record
Link to publication in ResearchOnline
Citation for published version (Harvard):
Fatani, S, Abubakari, A-R, Itua, I, Wong, C, Thomas, C & Naderali, EK 2012, 'Effect of diet-induced obesity on
protein expression in insulin signalling pathways of skeletal muscle in male Wistar rats', International Journal of
General Medicine, vol. 5, pp. 573-582. https://doi.org/10.2147/IJGM.S31819
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
Take down policy
If you believe that this document breaches copyright please view our takedown policy at https://edshare.gcu.ac.uk/id/eprint/5179 for details
of how to contact us.
Download date: 29. Apr. 2020
© 2012 Fatani et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
International Journal of General Medicine 2012:5 573–582
International Journal of General Medicine
Effects of diet-induced obesity on protein 
expression in insulin signaling pathways  







1Obesity Biology Unit, School of 
Clinical Sciences, University of 
Liverpool, 2Department of Health 
Sciences, Liverpool Hope University, 
Hope Park, 3Aintree University 
Hospital NHS Foundation Trust, 
Liverpool, UK
Correspondence: Ebrahim K Naderali 
Department of Health Sciences,  
Liverpool Hope University, Hope  
Park Campus, Liverpool, L16 9JD, UK 
Tel +44 015 1291 3439 
Fax +44 015 1291 3414 
Email naderae@hope.ac.uk
Background: The prevalence of diet-induced obesity is increasing globally, and posing 
significant health problems for millions of people worldwide. Diet-induced obesity is a major 
contributor to the global pandemic of type 2 diabetes mellitus. The reduced ability of muscle 
tissue to regulate glucose homeostasis plays a major role in the development and prognosis of 
type 2 diabetes. In this study, an animal model of diet-induced obesity was used to elucidate 
changes in skeletal muscle insulin signaling in obesity-induced diabetes.
Methods: Adult male Wistar rats were randomized and assigned to either a control group or to 
a test group. Controls were fed a standard laboratory pellet diet (chow-fed), while the test group 
had free access to a highly palatable diet (diet-fed). After 8 weeks, the diet-fed animals were 
subdivided into three subgroups and their diets were altered as follows: diet-to-chow, diet-fed 
with addition of fenofibrate given by oral gavage for a further 7 weeks, or diet-fed with vehicle 
given by oral gavage for a further 7 weeks, respectively.
Results: Untreated diet-fed animals had a significantly higher body weight and metabolic 
profile than the control chow-fed animals. Intramuscular triacylglyceride levels in the untreated 
obese animals were significantly higher than those in the control chow-fed group. Expression 
of protein kinase C beta, phosphatidylinositol 3, Shc, insulin receptor substrate 1, ERK1/2, and 
endothelial nitric oxide synthase was significantly increased by dietary obesity, while that of 
insulin receptor beta, insulin receptor substrate 1, and protein kinase B (Akt) were not affected 
by obesity.
Conclusion: These data suggest that diet-induced obesity affects insulin signaling mechanisms, 
leading to insulin resistance in muscle.
Keywords: diet-induced obesity, intramuscular lipids, insulin signaling, muscle, fenofibrate
Introduction
Insulin resistance is a comorbidity of overweight and obesity, and is a risk factor for 
development of type 2 diabetes and cardiovascular disease. In obese individuals and 
patients with type 2 diabetes, insulin resistance in skeletal muscle is characterized 
by markedly blunted insulin-stimulated glucose uptake and metabolism.1 Given that 
skeletal muscle is the primary site of glucose disposal in the human body, the inability 
of this tissue to take up glucose in response to insulin would account significantly 
for reduced in vivo disposal of plasma glucose in insulin-resistant individuals. At the 
cellular level, metabolic insulin resistance in diet-induced obesity shows disrupted 
protein expression and activation (mainly in skeletal muscle and liver) of signaling 
via the insulin receptor substrate 1 (IRS-1) phosphatidylinositol (PI)3 kinase pathway, 
accompanied by a reduction in glucose uptake and utilization.2,3
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Systemic lipid accumulation and an increase in the intra-
muscular concentrations of lipid intermediates, such as fatty 
acyl-CoA, ceramides, and diacylglycerides, not only correlate 
with insulin resistance, but also directly and indirectly alter 
insulin signaling.4–6 Considerable evidence linking increased 
skeletal muscle lipid content with insulin resistance has been 
derived from animal studies using acute and chronic high-
fat diets.7 Moreover, it has been documented that protein 
kinase C (PKC) causes insulin resistance in skeletal muscle.8 
 Furthermore, among the eight PKC isoforms, PKC-β appears 
to be the only isoform which is increased in insulin-resistant 
muscle. Indeed, insulin increases PKC-β in the muscle tis-
sue of obese patients but not of lean individuals, while basal 
PKC-β is reported to be higher in muscle tissue from obese 
individuals incubated in vitro.9 Moreover, intramuscular lipid 
intermediates, such as fatty acyl-CoA, ceramides, and dia-
cylglycerides, inhibit steps in the insulin signaling cascade.6 
Ceramide activates a protein phosphatase that dephosphory-
lates protein kinase B (Akt), resulting in inhibition of GLUT4 
translocation and glycogen synthesis.10,11
There is a close relationship between insulin resistance 
and visceral adiposity. It has become apparent that insulin 
sensitivity is modulated by adiposity, and this has led to a 
significant interest in adipocytokines, such as tumor necrosis 
factor alpha, leptin, and C-reactive protein, which may play 
a pivotal role in insulin signaling and resistance in skeletal 
muscle.12 Moreover, insulin sensitivity is restored by treat-
ments that reduce intramuscular lipid accumulation, such as 
lifestyle modification (ie, low-fat feeding, fasting, and exer-
cise) and pharmacological therapy (eg, fenofibrate, an acti-
vator of peroxisome proliferator-activated receptor alpha), 
which improve the lipid profile and insulin resistance.13–16 
To elucidate further the exact molecular mechanism(s) 
involved in insulin transduction in skeletal muscle, this 
study investigated PI3 kinase and mitogen-activated protein 
kinase expression in insulin signaling pathways in the skeletal 
muscle of rats with diet-induced obesity, and analyzed the 
relationship between lipid profile, protein expression, and 
induction of insulin resistance in skeletal muscle.
Materials and methods
Experimental protocol
Adult male Wistar rats (n = 40, weighing 195 ± 4 g) were 
randomized to a control group (n = 10) or to a test group 
(n = 30). Animals from each group were housed in pairs. 
Controls were fed a standard laboratory pellet diet (chow-
fed), while the test group had free access to a highly palat-
able diet. The standard chow diet provided 1310 kJ/100 g 
total energy (carbohydrate 60%, protein 30%, and fat 10%) 
whereas the highly palatable diet provided 1010 kJ/100 g 
energy (carbohydrate 65%, protein 19%, and fat 16%). The 
highly palatable diet consisted of 33% powdered chow, 33% 
condensed milk (Nestle UK Ltd, Croydon, UK), and 7% 
sucrose (Tate and Lyle, London, UK) by weight, with the 
remaining being tap water. Chow-fed controls remained on 
their prospective diet for 15 weeks; after 8 weeks, animals fed 
the palatable diet were divided further into three subgroups 
(each group containing 10 animals). In the first subgroup, the 
palatable diet was removed and the standard chow diet was 
reintroduced (diet-to-chow); the second subgroup remained 
on the palatable diet and were given fenofibrate (fenofibrate-
treated, 50 mg/kg/day) by oral gavage for a further 7 weeks; 
and the third subgroup was diet-fed (untreated) and given 
vehicle (1% carboxymethylcellulose [Sigma, UK] at 1 mL/kg 
body weight) by oral gavage daily for a further 7 weeks.
On the day of the experiment (after 15 weeks) the rats 
were weighed and sacrificed by CO
2
 inhalation after 2 hours 
of fasting. Total body fat mass was measured immediately 
using a bioimpedance method (Tobec®, Biotec Instruments 
Ltd, Kimpton, UK). The gonadal and perirenal fat pads and 
gastrocnemius muscle were dissected and weighed. The 
gastrocnemius muscle was snap-frozen in liquid nitrogen 
for later molecular and biochemical analysis. Plasma was 
immediately separated by centrifugation before being fro-
zen for later measurement of glucose, insulin, nonesterified 
free fatty acids, triacylglycerides, and tumor necrosis factor 
alpha, using commercially available diagnostic kits (Roche 
and Sigma Diagnostics). All procedures were carried out 
according to institutional ethical guidelines.
Experimental procedures
Western immunoblotting
Western immunoblotting was carried out on the four 
experimental groups (chow-fed, vehicle, diet-to-chow, and 
fenofibrate-treated) to measure protein expression levels, ie, 
PKC-β, insulin receptor beta (IR-β), IRS-1, Pl3 kinase, Akt, 
Shc, ERK1/2, and endothelial nitric oxide synthase (eNOS), 
all of which are involved in the insulin signaling pathway 
in skeletal muscle.
Nonspecific binding proteins were discriminated by 
incubating the blot with a blocking buffer (5% milk powder 
and 1 × phosphate-buffered saline) at room temperature for 
one hour, followed by immunoblotting with the appropriate 
primary antibody (1:500 dilution) made up in blocking buf-
fer, and left overnight at 4°C. The following morning, the 
blots were washed in 1 × phosphate-buffered saline with 
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1% Tween and incubated with secondary antibody (1:1000), 
ie, a horseradish peroxidase-linked antirabbit (or antigoat, 
depending on the source of the species used for primary 
antibody) for one hour at room temperature. Proteins were 
detected using an enhanced chemiluminescence method. 
Positive controls were incubated for standardization of 
samples between blots, while molecular weight markers 
(Bio-Rad Laboratories Inc, Hercules, CA) were used for 
sizing of the bands. Densitometry was used to quantify the 
bands obtained.
Triacylglyceride content in gastrocnemius 
skeletal muscle samples
Triacylglyceride content was assessed in gastrocnemius 
skeletal muscle samples of all animals in the four experi-
mental groups. A small sample of gastrocnemius muscle 
(160–200 mg) was homogenized in 500 µL of distilled 
water using a Polytron homogenizer. The homogenate were 
centrifuged for 5 minutes at 13,000 × g, and the supernatants 
were transferred to Eppendorf tubes. A triacylglyceride assay 
was performed on the supernatant to detect triacylglyceride 
levels in the muscle samples.
Data interpretation and statistical analysis
For Western blotting, the data from the chow-fed (control) 
animals were expressed as a 100% response, and the results 
from the other three groups were normalized and then 
expressed as the percentage of their respective controls. Data 
are expressed as the mean ± standard error, and have a normal 
distribution (Shapiro–Wilk test). Statistical significance was 
tested using the Student’s t-test, repeated-measures (one-way 
analysis of variance, Bonferroni t-test), or Mann–Whitney 
U test, as appropriate. Results were considered statistically 
significant at P , 0.05.
Results
Body weight and metabolic changes
Animals given the palatable diet progressively gained more 
weight than their chow-fed counterparts. At the end of the 
study, the untreated diet-fed animals were significantly 
heavier than the chow-fed, diet-to-chow, and fenofibrate-
treated animals, and the body weight of the diet-to-chow and 
fenofibrate-treated animals was significantly (P , 0.001) 
lower than that of the untreated diet-fed group, but was 
significantly (P , 0.05) higher than that of the control 
chow-fed group (Table 1). Compared with the chow-fed 
controls, the untreated diet-fed group had a significantly 
(P , 0.001) higher total and epididymal perirenal fat mass, 
but a significantly (P , 0.001) lower total lean mass (Table 1). 
Similarly, plasma insulin, triacylglyceride, nonesterified free 
fatty acid, and tumor necrosis factor alpha levels were sig-
nificantly (P , 0.001) higher in the untreated diet-fed group 
compared with the chow-fed group (Table 1). Removal 
of the palatable diet or fenofibrate treatment significantly 
reversed palatable diet-induced changes in fat mass and 
metabolic parameters (Table 1). There were no significant 
differences in plasma glucose levels and gastrocnemius 
muscle mass between the four experimental groups (Table 1). 
However, the HOMA (Homeostasis Model Assessment ) 
index was significantly (P , 0.001) elevated in the group 
with untreated diet-induced obesity compared with the 
 control chow-fed group. There was no significant difference 
in the HOMA index between the fenofibrate-treated and 
 diet-to-chow groups and the chow-fed controls (Table 1).
Triacylglyceride content in gastrocnemius 
muscle
Triacylglyceride content was measured in the skeletal muscle 
tissue samples (Figure 1) from all four experimental groups, 
ie, chow-fed control, vehicle, diet-to-chow, and fenofibrate-
treated groups. Triacylglyceride levels in muscle samples 
from the vehicle group (untreated obese animals) were sig-
nificantly higher (70%, P , 0.05) in comparison with the 
chow-fed control group, while triacylglyceride levels from 
the other two groups (diet-to-chow and fenofibrate-treated) 
were comparable with that in the chow-fed controls, with no 
significant differences noted (Figure 1).
Protein kinase expression in skeletal 
muscle insulin signaling pathways
Compared with the chow-fed group, PKC-β expression was 
significantly increased in the vehicle (113%, P , 0.01) and 
fenofibrate-treated (137%, P , 0.05) groups, but not in the 
diet-to-chow group (Figure 2). IR-β protein expression was 
similar in all four experimental groups, with no significant 
difference between them (Figure 3A). Similar to IR-β, 
IRS-1 expression was comparable in all four groups, again 
with no significant differences between them (Figure 3B). 
Interestingly, concentrations of the regulatory subunit p85 
of PI3 kinase were significantly increased in the vehicle 
(77%, P , 0.005) and fenofibrate-treated (68%, P , 0.05) 
groups, but not in the diet-to-chow group compared with the 
chow-fed controls (Figure 4A). AKt protein expression in the 
vehicle group (diet-induced obese animals) did not change 
significantly in comparison with that in the chow-fed control 
group (Figure 4B). However, there was a marked reduction 
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Figure 1 Triglyceride content of gastrocnemius muscle in four experimental groups, ie, chow-fed, untreated dietary obese, diet-to-chow, and fenofibrate-treated groups. 
Notes: Data are presented as the mean ± standard error. *P , 0.05 versus chow-fed controls. TG content in skeletal muscle tissue in the untreated obese group was 
significantly higher than in the chow-fed group. 




























Figure 2 PKC-β protein expression in rat skeletal muscle. Equal amounts (40 mg/well) of protein were separated by SDS-PAGE and immunoblotted with PKC-β 
antibodies. 
Notes: The animal groups are: chow-fed, untreated dietary obese, diet-to-chow, and fenofibrate-treated. Data are presented as the mean ± standard error. Data are normalized 
to that of controls and expressed as a percentage of the chow-fed control group. *P , 0.05 versus chow-fed; $P , 0.05 versus vehicle; **P , 0.005 vs chow-fed. 
Abbreviations: C, chow-fed; V, untreated dietary obese; DC, diet-to-chow; F, fenofibrate-treated; PKC-β, protein kinase C beta; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis.
in AKt levels in the diet-to-chow (38%, P , 0.001) and 
fenofibrate-treated (24%, P , 0.05) groups when compared 
with the chow-fed group (Figure 4B). Expression of two pro-
tein kinases important in the mitogen-activated protein kinase 
pathway, namely Shc and ERK1/2, was measured. Compared 
with the chow-fed control group, Shc protein levels in the 
vehicle group were significantly increased (65%, P , 0.01, 
Figure 5A), while Shc expression in the other two experi-
mental groups (ie, diet-to-chow and fenofibrate-treated) was 
not significantly altered (Figure 5A). Expression of ERK1/2 
protein in the vehicle group was increased significantly by 
95%, P , 0.005) and was markedly decreased in the diet-
to-chow group (28%, P , 0.05) when compared with the 
control group (Figure 5B). Furthermore, ERK1/2 levels in 
skeletal muscle tissue were not significantly altered by treat-
ment with fenofibrate (Figure 5B). Like PI3 kinase, eNOS 
protein levels were markedly augmented in the vehicle group 
(98%, P , 0.001) and in the fenofibrate-treated group (105%, 
P , 0.001) in comparison with chow-fed controls. However, 
there were no significant changes in eNOS expression in 































Figure 3 Protein expression of (A) IR-β, and (B) IRS-1 in rat skeletal muscle. Equal amounts (40 mg/well) of protein were separated by SDS-PAGE and immunoblotted with 
IR-β or IRS-1 antibodies. 
Notes: The animal groups are: chow-fed, untreated dietary obese, diet-to-chow, and fenofibrate-treated. Data are presented as the mean ± standard error. Data are 
normalized to that of control group and expressed as a percentage of the chow-fed (control) group. There were no significant differences in protein expression between 
any of the groups. 
Abbreviations: C, chow-fed; V, untreated dietary obese; DC, diet-to-chow; F, fenofibrate-treated; IR-β, insulin receptor beta; IRS-1, insulin receptor substrate 1; SDS-PAGE, 


























 tissues from the diet-to-chow group compared with that from 
the chow-fed controls (Figure 6).
Discussion
Normal muscular insulin signaling is an important factor 
in the regulation of glucose metabolism. In fact, muscle 
insulin resistance is one of the major contributing factors 
in the development of diabetes mellitus. Insulin action in 
muscle involves a complex signaling pathway composed of 
a cascade of protein kinases. Their expression and activation/
deactivation play a crucial role in maintaining normal glucose 
homeostasis. Therefore, any reduced strength in this insulin 
transduction may lead to skeletal muscle insulin resistance, 
and ultimately to systemic insulin resistance.
In diet-induced obesity, intramuscular triacylglycerides 
(and their intermediates, ie, ceramides, fatty acyl-CoA, and 
diacylglycerides), hyperinsulinemia, and elevated levels of 
some adipocytokines induce muscular insulin resistance 
in a cooperative manner. This insulin resistance is thought 
to be secondary to disruption of protein expression and/or 
phosphorylation of PI3 and mitogen-activated protein kinase 
signaling pathways in skeletal muscle.
The present study demonstrates that diet-induced obe-
sity significantly increased the triacylglyceride content in 
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muscle compared with normal chow-fed control animals. 
Although the mechanism of triacylglyceride accumulation 
is not fully explained, reports have suggested that this may 
be in part be due to increased lipid uptake by muscle rather 
than a decrease in fatty acid oxidation.17 Furthermore, 
a number of studies have reported a lack of impact of 
reduction in fatty acid oxidation on increasing accumula-
tion of fatty acyl-CoA (a triacylglyceride intermediate) in 
muscle.13,17,18 The increased plasma triacylglyceride levels 
seen in this study and in previous reports3,19 suggest that 
it is reasonable to hypothesize a role of increased lipid 
uptake into muscle in subjects with diet-induced obesity 
and ultimately development of diet-induced diabetes. 
Interestingly, both methods of weight reduction (long-term 
removal of a highly palatable diet and administration of 
fenofibrate) caused marked reduction of elevated levels of 
intramuscular and plasma triacylglycerides. It is also rea-
sonable to hypothesize that these improvements occurred 
via two different mechanisms, ie, removing the highly 
palatable diet causes a reduction in total energy (calorie) 
intake and an improved plasma and muscle lipid profile, 
and fenofibrate treatment increases beta oxidation of fatty 
























Figure 4 Protein expression of (A) PI3 kinase, and (B) AKt in rat skeletal muscle. Equal amounts (40 mg/well) of protein were separated by SDS-PAGE and immunoblotted 
with PI3 kinase or AKt antibodies. 
Notes: The animal groups are: chow-fed, untreated dietary obese, diet-to-chow, and fenofibrate-treated. Data are presented as the mean ± standard error, normalized to 
that of the control group, and expressed as a percentage of the chow-fed (control) group. *P , 0.05; **P , 0.005 versus chow-fed; $P , 0.05 versus vehicle. 
Abbreviations: Akt, protein kinase B; C, chow-fed; V, untreated dietary obese; DC, diet-to-chow; F, fenofibrate-treated; SDS-PAGE, sodium dodecyl sulfate polyacrylamide 
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In the present study, PKC-β expression was markedly 
increased in the gastrocnemius muscle of rats with diet-induced 
obesity, and this was associated with insulin resistance, as 
indicated by an increase in the HOMA index, suggesting a 
role for PKC-β protein expression during glucose uptake 
in skeletal muscle.20,21 The triacylglyceride intermediates, 
fatty acyl-CoA and diacylglycerol, might activate PKC-β 
directly,22,23 which, in turn, may have negative effects on the 
insulin transduction cascade in muscle, ultimately reducing 
insulin-mediated glucose uptake from circulating plasma. 
In this study, treating obesity by lifestyle modification, ie, 
long-term withdrawal of a highly palatable diet, achieved 
complete normalization of PKC-β protein expression as well 
as improvement in intramuscular lipid accumulation and a 
subsequent decrease in systemic insulin resistance, indicated 
by a HOMA index similar to that of the chow-fed controls. 
However, pharmacological treatment of obesity in this 
study (ie, administration of fenofibrate) failed to reduce or 
normalize expression of PKC-β in muscle, despite a marked 
improvement in intramuscular and plasma lipid concentra-
tions and insulin resistance. It is possible that the elevated 
PKC-β levels seen in muscle samples from fenofibrate-treated 
animals could be due to excess production of reactive oxygen 
































Figure 5 Protein expression of (A) Shc, and (B) ERK1/2, in rat skeletal muscle.  
Notes: Equal amounts (40 mg/well) of protein were separated by SDS-PAGE and immunoblotted with Shc or ERK1/2 antibodies. The animal groups are: chow-fed, untreated 
dietary obese, diet-to-chow, and fenofibrate-treated. Data are presented as the mean ± standard error, normalized to that of the control group, and expressed as a 
percentage of the chow-fed (control) group. *P , 0.05; **P , 0.005 versus chow-fed; $P , 0.05 versus vehicle.
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The principal mechanism of lipid reduction by fenofibrate is 
stimulation of beta oxidation of fatty acids in tissues such as 
skeletal muscle.24 Reactive oxygen species are some of the 
end products of beta oxidation of fatty acids which may have 
a major role in increasing expression and phosphorylation of 
PKC-β.25,26 Furthermore, various reports have indicated that 
fenofibrate is associated with increased production and avail-
ability of reactive oxygen species,27–29 further underlined by 
the increased PKC-β levels seen in the fenofibrate-treated 
group in our study. Hence, our results indicate that diet-
induced obesity can cause increased expression of PKC-β in 
skeletal muscle, which augments systemic insulin resistance. 
Interestingly, in the present study, the increased PKC-β levels 
were reversed completely by long-term withdrawal of the 
highly palatable diet, but not by pharmacological interven-
tion using fenofibrate, indicating a key role for diet and/or 
its content in elevation of PKC-β.
Protein expression in the early steps of the PI3 kinase 
insulin signaling pathway, such as IR-β and IRS-1, was not 
affected by diet-induced obesity in our study. However, oth-
ers have reported amelioration of tyrosine phosphorylation of 
IRS-1 and IR-β in skeletal muscle from obese and diabetic 
patients.30,31 The deficiencies in phosphorylation could be 
mediated by increased protein expression and activation of 
PKC-β, which in turn phosphorylates IR-β and IRS-1 in ser-
ine residues, thereby reducing their ability to phosphorylate 
tyrosine and leading to insulin resistance.20,21,32 However, 
further studies are required to test this hypothesis.
Although, we did not measure IRS-2 protein expression 
in skeletal muscle in the current study, several studies have 
indicated that IRS-1 and IRS-2 are not functionally inter-
changeable in tissues that are responsible for glucose produc-
tion and glucose uptake, ie, skeletal muscle.33 Indeed, IRS-1 
appears to have its major role in skeletal muscle, whereas 
IRS-2 appears to regulate hepatic insulin action.34,35
Interestingly, in this study, diet-induced obesity resulted 
in a significant increase in protein expression of the regulatory 
subunit p85 of PI3 kinase in skeletal muscle. The increase in 
protein expression was synchronized with systemic insulin 
resistance. Therefore, it could be postulated that an increased 
level of the p85 regulatory subunit might inhibit PI3 kinase 
activity by competing with phosphotyrosine targets. Hence, 
disruption of the balance between the amounts of PI3 kinase 
subunits and excess levels of the p85 regulatory subunit could 
contribute to insulin resistance. This hypothesis is supported 
by studies of insulin-resistant states induced by human 
placental growth hormone, obesity, and type 2 diabetes.36,37 
Therefore, if p85 production can be enhanced nutritionally, 
the resulting changes in the ratio of p85 to p110 may be the 
earliest manifestation of the ensuing insulin resistance. This 




























Figure 6 Protein expression of eNOS in rat skeletal muscle.  
Notes: Equal amounts (40 mg/well) of protein were separated by SDS-PAGE and immunoblotted with eNOS antibodies. The animal groups are: chow-fed, untreated dietary 
obese, diet-to-chow, and fenofibrate-treated. Data are presented as the mean ± standard error, normalized to that of the control group, and expressed as a percentage of 
the chow-fed (control) group. *P , 0.01 versus chow-fed; $P , 0.05 versus vehicle. 
Abbreviations: C, chow-fed; V, untreated dietary obese; DC, diet-to-chow; F, fenofibrate-treated; insulin receptor substrate 1; SDS-PAGE, sodium dodecyl sulfate 
polyacrylamide gel electrophoresis; eNOS, endothelial nitric oxide synthase.
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AKt protein expression in skeletal muscle did not change 
in response to diet-induced obesity. Similar findings have 
been reported whereby phosphorylation of AKt in skeletal 
muscle from insulin-resistant obese diabetic subjects was 
not changed significantly.38,39 Taken together, it can be 
argued that AKt in skeletal muscle has no role in inducing 
muscular insulin resistance. However, chronic withdrawal 
of the highly palatable diet in our study caused a significant 
reduction in AKt protein levels compared with the control 
group, despite complete normalization of systemic insulin 
resistance as indicated by normalization of the HOMA index, 
further indicating the lack of a significant role for AKt in 
insulin resistance in skeletal muscle. Similarly, fenofibrate-
treated animals had lower AKt levels in skeletal muscle, 
despite improved insulin signaling and lipid concentrations in 
muscle. This is in agreement with previous studies showing 
marked attenuation of AKt phosphorylation and AKt levels 
in human cells in vitro in response to fenofibrate.40,41
In the present study, diet-induced obesity significantly 
increased the expression of ERK1/2 and Shc, whereas 
removal of the highly palatable diet or treatment with feno-
fibrate abolished the increase in protein expression of both 
ERK1/2 and Shc. This is in agreement with previous reports 
whereby diet-induced obesity increased ERK1/2 expression 
while hyperinsulinemia resulted in a marked increase in Shc 
expression.42,43 These findings suggest important roles for 
ERK1/2 and Shc in insulin resistance in skeletal muscle. 
Furthermore, eNOS expression was significantly increased in 
the group fed the highly palatable diet, which may indicate a 
role of high caloric intake in eNOS expression. We have pre-
viously reported a significant increase in eNOS expression in 
the vascular tissue of obese rats but not in liver samples.3,44 It 
is suggested that increased eNOS expression may be second-
ary to increases in adipokines, such as tumor necrosis factor 
alpha; however, this is in contrast with a previous report of 
tumor necrosis factor alpha in fact downregulating eNOS 
expression in muscle tissue.45 Therefore, this hypothesis 
merits further investigation.
In summary, it could be postulated that dietary-induced 
muscular insulin resistance is a consequence of a series 
of defects in the insulin signaling pathway resulting from 
impaired expression of PKC-β, PI3 kinase, ERK1/2, Shc, 
and eNOS. The exact mechanism is not fully understood, 
but it is likely that excessive triacylglyceride levels in muscle 
tissue may have detrimental effects on protein expression in 
insulin signaling. This in turn may reduce insulin’s primary 
action on skeletal muscle as a glucose homeostasis agent in 
obesity induced diabetes.
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